Title |
Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib
|
---|---|
Published in |
Frontiers in oncology, July 2017
|
DOI | 10.3389/fonc.2017.00150 |
Pubmed ID | |
Authors |
Kellie Lynn Nelson, David Stenehjem, Meghan Driscoll, Glynn Weldon Gilcrease |
Abstract |
A 60- to 65-year-old female on prior statin therapy was initiated on palbociclib and fulvestrant for the treatment of metastatic, hormone-receptor positive breast cancer. She subsequently developed sudden progressive muscle weakness that progressed to death within weeks. The patient noticed progressive proximal muscle weakness after two cycles of palbociclib, with no other medication changes in the interim. This rapidly progressed and resulted in death within 7 days of presentation to hospital. There has been one previous report of rhabdmyolysis with palbociclib, occurring in a patient on concomitant statin. In this report, we discuss the possible aetiologies of this progressive rhabdomyolysis including time-dependent inhibition of CYP3A4 or inhibition of hepatic uptake transporters, e.g., OATP1B1. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 25 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 5 | 20% |
Student > Ph. D. Student | 3 | 12% |
Researcher | 3 | 12% |
Student > Master | 3 | 12% |
Other | 2 | 8% |
Other | 2 | 8% |
Unknown | 7 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 32% |
Biochemistry, Genetics and Molecular Biology | 3 | 12% |
Nursing and Health Professions | 3 | 12% |
Agricultural and Biological Sciences | 1 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Other | 2 | 8% |
Unknown | 7 | 28% |